Nuclear Imaging

Molecular imaging, also called nuclear imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI. 

Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status
News | Radiopharmaceuticals and Tracers
Shine Medical Announces its Isotope Production Facility is Weathertight

March 26, 2021 — Shine Medical Technologies LLC announced that construction of the exterior structure of its first-of-a ...

Time March 26, 2021
arrow
NorthStar poised to be first commercial-scale supplier of important therapeutic radioisotopes Copper-67 (Cu-67) and Actinium-225 (Ac-225); Initial specialized SPECT imaging portfolio includes fibrin-targeted FibroScint, with potential indications in cardiovascular disease
News | SPECT Imaging
NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals

March 16, 2021 — NorthStar Medical Radioisotopes, LLC announced organizational changes to drive focused growth for its ...

Time March 16, 2021
arrow
The phantom used for hyperpolarized imaging, with an illustration of imaging slices acquired using the new technique. photo/©: Laurynas Dagys, University of Southampton
News | Nuclear Imaging
Hyperpolarized Proton MRI Used to Observe Metabolic Processes in Real Time

March 12, 2021 — Magnetic resonance imaging (MRI) is already widely used in medicine for diagnostic purposes ...

Time March 12, 2021
arrow
Diagnostic imaging studies using Tc-99m inform healthcare decisions for approximately 30 million patients annually around the world
News | Nuclear Imaging
IBA and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Tc-99m

March 8, 2021 — IBA (Ion Beam Applications S.A., EURONEXT) and NorthStar Medical Radioisotopes, LLC, announced a ...

Time March 08, 2021
arrow
Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the Biograph Vision Quadra, a positron emission tomography/computed tomography (PET/CT) scanner designed for clinical use as well as translational research – or the application of scientific research to create therapies and procedures that improve health outcomes. In this manner, the Biograph Vision Quadra expands precision medicine.
News | PET-CT
Siemens Healthineers Announces FDA Clearance of Biograph Vision Quadra Extended Axial FoV PET/CT Scanner

March 8, 2021 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the Biograph ...

Time March 08, 2021
arrow
Axial fused PET/CT image shows intense uptake (arrowhead) in the deep pelvis corresponding to the left lobe of the prostate in a 62-year-old with a history of prostate cancer treated with radiation therapy. The CT scan does not show the tumor. Image courtesy of the the Radiological Society of North America.
Feature | Treatment Planning | By Melinda Taschetta-Millane
Using PET to Enhance Prostate Treatment Planning

The decision to offer radiation after prostatectomy for patients with recurrent prostate cancer is quite complex, and ...

Time March 05, 2021
arrow
CT imaging radiation dose tracking software from Imalogix displayed at RSNA 2019.
Feature | Radiation Dose Management | By Dave Fornell
Medical Imaging Radiation Exposure in U.S. Dropped Over Past Decade

More than a decade ago, there was an alarming, rapid rise in ionizing radiation exposure in the U.S. population that was ...

Time March 04, 2021
arrow
Findings indicate that PPC and GG are highly predictive of overall upstaging by PSMA PET/CT for patients with high-risk prostate cancer
News | PET-CT
Model Helps Predict Which Patients will Benefit Most from PSMA PET Scan

February 23, 2021 — A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center helps identify which ...

Time February 23, 2021
arrow
F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.
News | Molecular Imaging
Molecular Imaging Determines Effectiveness of Novel Metastatic Breast Cancer Treatment

February 22, 2021 — Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2 ...

Time February 22, 2021
arrow
Bright spots indicate that cancer cells have responded to a one-day challenge with estrogen in this positron emission tomography (PET) scan of a woman with breast cancer. In a small study, researchers at Washington University School of Medicine in St. Louis found that only women whose tumors responded to estrogen challenge benefited from hormone therapy. The findings could help doctors choose the treatments most likely to help their patients. Image courtesy of Farrokh Dehdashti
News | PET Imaging
Imaging Identifies Breast Cancer Patients Unlikely to Benefit from Hormone Therapy

February 3, 2021 — Hormone therapy commonly is given as a targeted treatment for women whose cancer cells carry ...

Time February 03, 2021
arrow
NMP to evaluate technology to create new class of PET radiopharmaceuticals
News | PET Imaging
Fuzionaire Radioisotope Technologies K.K. and Nihon Medi-Physics Enter Feasibility Study Agreement

January 29, 2021 — Fuzionaire Radioisotope Technologies K.K. (“FRIT”) announced that it has entered into a feasibility ...

Time January 29, 2021
arrow
Clinical utility of Axumin (fluciclovine F 18) being investigated in expanded areas of cancer imaging
News | PET Imaging
Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases

January 18, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time January 18, 2021
arrow
Differences in brain activity between connected and disconnected states of consciousness studied with positron emission tomography (PET) imaging. Activity of the thalamus, anterior (ACC) and posterior cingulate cortices (PCC), and bilateral angular gyri (AG) show the most consistent associa-tions with the state of consciousness (A = general anesthesia, B = sleep). The same brain struc-tures, which are deactivated when the state of consciousness changes to disconnected in general anesthesia or natural sleep
News | PET Imaging
Imaging the Twilight Zone

December 30, 2020 — What happens in the brain when our conscious awareness fades during general anesthesia and normal ...

Time December 30, 2020
arrow
A multidisciplinary team of researchers have demonstrated production, purification, and potential for the 134Ce/134La in vivo generator as a PET imaging surrogate for 225Ac and 227Th radiotherapeutic agents.
News | Nuclear Imaging
New Diagnostic Isotope to Enhance Targeted Alpha Therapy for Cancer

December 22, 2020 — Researchers in the DOE Isotope Program have developed an effective radionuclide, cerium-134, as a ...

Time December 22, 2020
arrow
SHINE executives and project leaders were joined by a City of Janesville official for the groundbreaking ceremony for the new corporate headquarters and therapeutics production facility on the SHINE campus in Janesville, Wis. (Photo: Business Wire)
News | Nuclear Imaging
SHINE Medical Breaks Ground for 54,000-Square-Foot Headquarters and Therapeutics Production Facility

December 18, 2020 — SHINE Medical Technologies LLC today announced that the company has broken ground on a new 54,000 ...

Time December 18, 2020
arrow
Researchers at the Beckman Institute for Advanced Science and Technology developed a subspace mass spectrometry imaging approach that accelerates the speed of data acquisition -- without sacrificing the quality -- by designing a model-based reconstruction strategy.
News | SPECT Imaging
Computational Method Provides Faster High-resolution Mass Spectrometry Imaging

December 15, 2020 — A new computational mass spectrometry imaging method enables researchers to achieve high mass ...

Time December 15, 2020
arrow
CXCR4-directed PET correlates with MRI-determined lymphoma lesions. Depicted are representative MR images (T1c- and FLAIR- sequences), and the corresponding CXCR4- directed PET images and fusion images (MRI-FLAIR and PET), of two patients with PCNSL and SCNSL, respectively. Images created by Department of Nuclear Medicine, School of Medicine, Technische Universität München, Munich, Germany.
News | PET Imaging
PET Imaging Tracer Effective for Diagnosing and Managing Rare CNS B-cell Lymphoma

December 14, 2020 — Positron emission tomography (PET) imaging with 68Ga-pentixafor is an effective diagnostic tool for ...

Time December 14, 2020
arrow
News | Nuclear Imaging
The Journal of Nuclear Medicine Celebrates 60 Years of Research

December 14, 2020 — The Journal of Nuclear Medicine (JNM) has issued a special supplement commemorating six decades of ...

Time December 14, 2020
arrow
Post-neoadjuvant therapy changes in metabolic metrics from PET/MRI and morphologic metrics from CT were associated with pathologic response and overall survival in patients with pancreatic ductal adenocarcinoma
News | PET-MRI
PET/MRI, CT Metrics Assess Pathologic Response of Pancreas Cancer to Neoadjuvant Therapy

December 10, 2020 — According to an open-access Editor's Choice article in ARRS' American Journal of Roentgenology (AJR) ...

Time December 10, 2020
arrow
Videos | PET-CT
VIDEO: Example of PET-CT Artificial Intelligence Driven Image Reconstruction

This is an example of Canon's Advanced intelligent Clear-IQ Engine (AiCE) AI-driven image reconstruction software that ...

Time December 04, 2020
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now